


# Prevalence and Antibiotic Resistance of *Stenotrophomonas maltophilia* in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot

Health Services Research and  
Managerial Epidemiology  
Volume 6: 1-9  
© The Author(s) 2019  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/2333392819870774  
journals.sagepub.com/home/hme  


Márió Gajdács<sup>1,2</sup>  and Edit Urbán<sup>3</sup>

## Abstract

**Background:** Since the 1980s, *Stenotrophomonas maltophilia* has emerged as an important pathogen associated with significant mortality in pneumonia and bacteremia of severely immunocompromised, hospitalized patients. The drug of choice in *S maltophilia* infections is sulfamethoxazole-trimethoprim (SMX/TMP); SMX/TMP resistance is a serious concern in clinical practice. The aim of this study was to assess the prevalence of *S maltophilia* in lower respiratory tract (LRTI) samples at a tertiary-care university hospital.

**Methods:** This retrospective cohort study was carried out using microbiological data collected between January 2008 and December 2017. Routine antimicrobial susceptibility testing was performed for SMX/TMP and levofloxacin; in case of resistance, susceptibility testing for additional antibiotics (tigecycline, amikacin, and colistin) was also performed.

**Results:** A total of 579 individual *S maltophilia* isolates were identified (2008-2012:  $n = 160$ , 2013-2017:  $n = 419$ ;  $P = .0008$ ). In all, 78.46% of patients were younger than 5 or older than 50 years of age and had recent trauma, surgery, or underlying conditions (malignancies, respiratory distress syndrome, congenital disorders, and cystic fibrosis). In 28.16% of samples, more than 1 pathogen was identified, and 5.35% of coisolated pathogens were multidrug resistant (MDR). In all, 12.1% of isolates were SMX/TMP-resistant (2008-2012: 6.12%, 2013-2017: 18.06%;  $P = .034$ ), while 8.99% were resistant to levofloxacin (2008-2012: 7.86%, 2013-2017: 10.12%;  $P > .05$ ). SMX/TMP resistance was detected more frequently in samples originating from inpatients ( $n = 2.50 \pm 2.39$  vs  $n = 11.50 \pm 3.76$ ;  $P = .0002$ ).

**Conclusions:** In all, 5.87% of isolates were extensively drug resistant (XDR), that is, in addition to SMX/TMP, they were resistant to levofloxacin, amikacin, colistin, and tigecycline. The results of our study correspond to the findings in the literature.

## Keywords

*Stenotrophomonas maltophilia*, pneumonia, tracheobronchitis, sulfamethoxazole/trimethoprim, levofloxacin, colistin, antibiotic resistance, tigecycline

## Introduction

*Stenotrophomonas maltophilia* is a nonfermenting Gram-negative rod that is ubiquitous in nature (predominantly occurring in aquatic environments and on plants)<sup>1</sup>. Biochemically, it is catalase positive and oxidase negative, and it produces acid from maltose (hence the name “*maltophilia*”).<sup>2,3</sup> Due to its charged cell wall surface and biofilm production, it may attach to and survive on abiotic surfaces in clinical settings (eg, central venous catheters, disinfectant and hand-washing solutions, solutions for hemodialysis, endoscopes, inspiration/expiration circuits of ventilators, nebulizers, tap water, and showerheads).<sup>1,4-7</sup> This

<sup>1</sup> Faculty of Pharmacy, Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary

<sup>2</sup> Faculty of Medicine, Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary

<sup>3</sup> Faculty of Medicine, Department of Public Health, University of Szeged, Szeged, Hungary

Submitted July 11, 2019. Revised July 30, 2019. Accepted July 30, 2019.

### Corresponding Author:

Márió Gajdács, Faculty of Pharmacy, Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös utca 6, Szeged, Csongrád 6720, Hungary.

Email: gajdacs.mario@pharm.u-szeged.hu



pathogen is frequently responsible for nosocomial outbreaks, especially in intensive care units (ICUs).<sup>6,8,9</sup> Before the 1980s, there have been seldom reports of the isolation of this microorganism in the context of human infections<sup>10</sup>; however, after the 1980s, the prevalence of nosocomial infections associated with *S. maltophilia* has increased rapidly.<sup>11</sup> On the one hand, *S. maltophilia* is a pathogen of low virulence and limited invasiveness; therefore, bypassing the natural defenses of the body is crucial for the development of any pathologies.<sup>1,4,10-12</sup> Advancements in medical interventions (complex surgeries, chemotherapy of advanced malignancies, immunosuppressive therapy for organ transplantation, or autoimmune disorders) have also resulted in the increase in the number of patients at risk.<sup>1,4,10-12</sup> Nonetheless, advancements in the identification methods in clinical microbiology laboratories (eg, polymerase chain reaction, mass spectrometry, and sequencing) have allowed for the more precise identification of this pathogen.<sup>13-15</sup> To complicate things even further, the prevalence of community-acquired *S. maltophilia* infections (presumably due to the increase in the number of immunocompromised/debilitated patients in outpatient care settings) has also increased since the 2000s.<sup>16</sup>

The main clinical manifestations of *S. maltophilia* infections include nosocomial lower respiratory tract infections (LRTIs; namely, tracheobronchitis/pneumonia, usually associated with mechanical ventilation) and bacteremia. Nevertheless, other manifestations, for example, wound/soft tissue infections (ie, ecthyma gangrenosum), cellulitis, mastoiditis, meningitis, peritonitis, bone and joint infections, urinary tract infections, conjunctivitis, and otitis media have also been described.<sup>4,9-11</sup> These infections usually occur in severely debilitated, immunosuppressed individuals, in addition to patients with a chronic illness or a developmental abnormality affecting a specific organ system.<sup>4,9-11,17-19</sup> *Stenotrophomonas maltophilia* represents the fourth most common pathogen among nonfermenting gram-negative bacteria (following *Pseudomonas aeruginosa*, *Acinetobacter* spp, and *Burkholderia cepacia* complex), with a reported incidence of 7.1 to 37.7 cases/10 000 discharges (regarding nosocomial infections)<sup>20</sup>. *Stenotrophomonas maltophilia* infections are associated with a high crude mortality of 25% to 75% in case of pneumonia and 20% to 60% in case of bacteremia.<sup>3</sup> The mortality rate increases sharply if the patients receive inappropriate antimicrobial therapy (which mainly occurs empirically)<sup>3,4,9-11</sup>.

*Stenotrophomonas maltophilia* may colonize the respiratory tract and persist in the sputum of these patients for a long period of time; therefore, it may be difficult to ascertain the clinical significance of a positive culture result from the microbiology laboratory.<sup>21,22</sup> However, previously verified colonization is one of the main risk factors for manifestation of *S. maltophilia* LRTI; thus, culture positivity for this microorganism does pertain clinically useful information.<sup>6,21,22</sup> While some reports suggest that *S. maltophilia* LRTIs are characterized by the lack of acute inflammatory response, Di Bonaventura et al found an pronounced inflammatory response (increased expression of IL-8 and TNF- $\alpha$ ) in murine airway epithelial cells and macrophages, which may contribute to airway inflammation *in vivo*.<sup>23,24</sup> Histologically, *S. maltophilia* LRTIs are frequently characterized by

focal lung necrosis and lung hemorrhage, while pleural effusions and cavitations are rarely observed.<sup>20</sup> As many *S. maltophilia* infections are polymicrobial, clinicians should be extremely cautious when interpreting radiological findings (especially in patients with cancer), as several copathogens (eg, *Pseudomonas* spp, *Acinetobacter* spp, *Nocardia* spp, *Staphylococcus aureus*, and opportunistic fungi) may be present simultaneously.<sup>1,4,10-12</sup> In severely immunosuppressed patients, fatal hemorrhagic pneumonia may occur, which is the fulminant course of the infection.<sup>10-12</sup> In addition, *S. maltophilia* is a well-known colonizer and pathogen in patients with cystic fibrosis (CF); it has been described that the colonization/infection rate (especially in 10<sup>5</sup>-10<sup>6</sup> CFU) correlates well with disease progression and loss of lung function.<sup>25,26</sup> Air-borne transmission of this microorganism from the cough (aerosol) of patients with CF have also been described.<sup>25,26</sup>

The therapeutic options regarding *S. maltophilia* infections are very limited, owing to the intrinsic resistance of this pathogen to several classes of antibiotics:  $\beta$ -lactam antibiotics (most notably carbapenems) are hydrolyzed by zinc-dependent, chromosomally mediated  $\beta$ -lactamases (namely, L1 and L2), aminoglycosides (acetyl-transferases and temperature-dependent changes in the lipopolysaccharide), while a plethora of other drugs may be affected by the overexpression of energy-dependent efflux pumps.<sup>4,7,9-11,20</sup> Currently, the therapy of choice in these infections is a high-dose sulfamethoxazole/trimethoprim (SMX/TMP; cotrimoxazole)<sup>1,9-11</sup>. Although a recent publication by Ko et al has reported that fluoroquinolones (a popular alternative to cotrimoxazole) are equally effective in the therapy of these infections<sup>27</sup>, SMX/TMP resistance (among other things, as drug allergies may also be present) is a serious therapeutic challenge for clinicians. Due to the proclivity of this microorganism to become multidrug resistant (MDR) and extensively drug resistant (XDR), it has been listed by the World Health Organization as one of the most concerning multidrug resistant organisms worldwide.<sup>28</sup> Apart from SMX/TMP and fluoroquinolones, other drugs that may be considered for therapy (and several case reports are available in successfully curing patients) are the tetracyclines (doxycycline, minocycline, and tigecycline), ticarcillin/clavulanate, ceftazidime, colistin, and chloramphenicol<sup>4,7,9-11,20</sup>.

Despite the abundance of global surveillance studies published, there are only few reports assessing the microbiological and clinical significance of *S. maltophilia* in LRTIs, as the majority of studies have focused on the isolation of MDR *Pseudomonas* spp and *Acinetobacter* spp. The aim of this study was to assess the prevalence of *S. maltophilia* in respiratory tract specimens at a tertiary-care hospital in Hungary retrospectively, during a 10-year study period (2008-2017).

## Materials and Methods

### Characteristics of the Study and the Clinical Center

This study was performed on the basis of retrospectively collected microbiological data regarding a 10-year time period on

January 1, 2008, to December 31, 2017. Our institute is the dedicated microbiological diagnostic laboratory of a 1820-bed tertiary-care teaching hospital in Szeged (Hungary), which is responsible for the medical care of >400 000 patients in the southern region of Hungary. Data were collected by an electronic search of the Institutional laboratory information system records for the designated time period, which was conducted by the authors. Isolates were considered separate if their isolation happened >14 days apart, or *S maltophilia* isolates with different antibiotic susceptibility results were detected from the same patient. Polymicrobial infection was defined by the isolation of more than 1 organism in a single sample.<sup>29</sup> As a part of this study, data on the affected patients were also collected, which was limited to demographic characteristics (age, sex, and inpatient/outpatient status) and the indication for sample submission. The relevant data were collected if *S maltophilia* was isolated in significant colony count from the samples of the abovementioned patients. The study was deemed exempt from ethics review by the institutional review board, and informed consent was not required as data anonymity was maintained.

### Processing of Microbiological Samples, Identification, and Susceptibility Testing

Respiratory sampling from patients was performed in line with current recommendations with international guidelines, respective to each individual sample type. The processing of respiratory tract samples was based on current international guidelines of routine clinical bacteriology; culture plates were incubated at 37°C for 24 to 48 hours, aerobically. For bacterial identification, classical phenotypic methods and VITEK 2 Compact ID/AST (bioMérieux, Marcy-l'Étoile, France) were used between 2008 and 2012; however, starting with 2013, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Germany) was introduced to the diagnostic workflow of our laboratory. Sample preparation methods and technical specifications for MALDI-TOF MS measurements are described elsewhere.<sup>30</sup> Susceptibility testing for *S maltophilia* isolates was performed for SMX/TMP and levofloxacin routinely; if SMX/TMP resistance was detected, supplementary antibiotics (tigecycline, amikacin, and colistin) were also tested. The susceptibility testing methods utilized and the interpretative criteria were described elsewhere in detail.<sup>29</sup>

### Statistical Analyses

Data for analysis were collected from the MedBakter laboratory information system, while the management of data and the preparation of data for statistical analyses were performed using Microsoft Excel 2013 (Microsoft Corp, Redmond, Washington). Statistical analyses were performed with SPSS software version 24 (IBM SPSS Statistics for Windows 24.0; IBM Corp Armonk, New York). The normality of variables was tested using Shapiro-Wilk tests. *P* values <.05 were considered statistically significant.

## Results

A total of 579 *S maltophilia* isolates were identified ( $57.9 \pm 31.0$ /year, highest in 2015, lowest in 2008) from various respiratory samples between 2008 and 2017. The number of isolates between 2008 and 2012 was  $n = 160$  ( $32.0 \pm 5.33$ /year, range: 24-38), while for 2013 to 2017 this number was  $n = 419$  ( $83.8 \pm 21.53$ /year, range: 55-111). A sizable ( $P = .0008$ ) increase was observed in the detection of *S maltophilia* in the second part of the study period (2013-2017). The affected patients presented with a pronounced male dominance (female-to-male ratio: 0.69; 63.84% male); the median age of the affected patients was 55 years (range: 0-96 years), both in the inpatient and outpatient groups. The age distribution of patients was as follows: 16.03% 0 to 5 years, 3.84% 6 to 17 years, 6.51% 18 to 35 years, 11.20% 36 to 50 years, 26.24% 51 to 65 years, and 36.19% of patients were older than 65 years.

Tracheal aspirates were the most common samples type (65.28%), followed by sputum samples (17.20%), bronchoalveolar lavage (BAL; 16.82%, including and bronchoscopic BAL and MiniBAL), in addition to samples attained through pleural and pericardial puncture (0.35% each). Indications for the submission of the abovementioned positive samples included septicemia (19.17%), hematological malignancies (predominantly acute myeloid leukemia) and solid tumors (lung, stomach, and colon cancer; 16.23%), recent trauma, burns or invasive surgery (13.47%), congenital disorders or preterm delivery (12.78%), pneumonia, pleuritis or acute respiratory distress syndrome (11.07%), cardiovascular illnesses (10.89%), cystic fibrosis (6.91%), meningitis (5.54%), or other reasons (3.94%). The largest amount of isolates originated from the intensive care units (which has 3 subsections, namely, cardiology-hematology, surgery, and traumatology; 47.49%), department of internal medicine (27.29%), department of pediatrics and neonatology (9.86%), department of otorhinolaryngology, head and neck surgery (8.11%), department of oncology (5.78%), and other affiliated institutions (1.47%). At the time of isolation, 24.89% of affected patients were treated as outpatients; the number of isolates from outpatient samples was significantly higher in the second half of the study period ( $n = 40$  vs  $n = 103$ ;  $P < .04$ ).

In 71.84% of relevant respiratory samples, *S maltophilia* was the only isolated pathogen, whereas in 28.16%, more than 1 (2 in 18.13%, 3 in 6.05%, 4 in 2.76%, and 5 or more in 1.21%) different species could be isolated (Table 1). Other nonfermenting Gram-negative and *Candida* species were the most frequent species coisolated. *Pseudomonas aeruginosa* (in 57 cases) and *C albicans* (in 54 cases) were the most frequent coisolates; 5.35% of coisolated pathogens were MDR (including MDR *P aeruginosa*, methicillin-resistant *S aureus* [MRSA], and extended-spectrum  $\beta$ -lactamase-producing [ESBL] *Enterobacteriaceae*).

During the 10-year period, almost 88% (87.90%) of respiratory *S maltophilia* were susceptible to SMX/TMP, while levofloxacin susceptibility (Minimum Inhibitory Concentration [MIC] range: 0.5-64 mg/L) was shown to be somewhat

**Table 1.** Pathogens Coisolated With *Stenotrophomonas Maltophilia* in Respiratory Samples, 2008-2017.

Coisolates in Relevant Respiratory Samples	Frequency, n
<i>Pseudomonas aeruginosa</i>	57
<i>Candida albicans</i>	54
<i>Candida glabrata</i>	23
<i>Klebsiella pneumoniae</i> (including ESBL producers)	20
<i>Staphylococcus aureus</i> (including MRSA)	20
<i>Acinetobacter baumannii</i>	12
<i>Enterobacter cloacae</i> (including ESBL producers)	7
<i>Escherichia coli</i> (including ESBL producers)	6
<i>Candida tropicalis</i>	4
<i>Serratia marcescens</i>	4
<i>Proteus vulgaris</i>	4
<i>Candida krusei</i>	3
<i>Aspergillus fumigatus</i>	3
<i>Escherichia faecium</i>	3
<i>Morganella morganii</i>	3
<i>Acinetobacter niger</i>	2
<i>Candida inconspicua</i>	2
<i>Citrobacter freundii</i>	2
<i>Citrobacter freundii</i>	2
<i>Klebsiella oxytoca</i>	2
<i>Enterobacter cloacae</i>	1
<i>Enterobacter kobei</i>	1
<i>Hafnia alvei</i>	1

Abbreviations: ESBL, extended-spectrum  $\beta$ -lactamase MRSA, methicillin-resistant *Staphylococcus aureus*.

higher (91.01%). This left 12.1% of isolates (2008-2012: 6.12%; 2013-2017: 18.06%;  $P = .034$ ) resistant to SMX/TMP and 8.99% of isolates (2008-2012: 7.86%; 2013-2017: 10.12%;  $P > .05$ ) resistant to levofloxacin, respectively. Of the SMX/TMP-resistant *S maltophilia* strains, 71.42% was also resistant to amikacin (MIC range: 1-32 mg/L), 10.20% for tigecycline (MIC range: 1-32 mg/L), and 8.57% for colistin (MIC range: 0.25-256 mg/L). It is worth noting that in 5.87% of isolates, resistance to SMX/TMP, levofloxacin, amikacin, tigecycline, and colistin was present simultaneously; therefore, these isolates should be considered XDR strains. The SMX/TMP resistance was detected more frequently in samples originating from inpatients ( $n = 2.50 \pm 2.39$  vs  $n = 11.50 \pm 3.76$ ;  $P = .0002$ ), while a numerical but not statistical tendency was observed for levofloxacin resistance ( $n = 4.49 \pm 0.23$  vs  $n = 5.86 \pm 0.91$ ;  $P = .078$ ).

## Discussion

The amount of specific studies regarding the prevalence and resistance trends of *S maltophilia* isolates in LRTI samples is very limited, the available literature concerning this topic is summarized by the authors in Table 2. *Stenotrophomonas maltophilia* LRTIs are thought to be infrequent, but their clinical relevance is increasing in the era of surgical interventions and heavily immunosuppressed patients.<sup>1-4,9-11,16-22</sup> The presence of obstruction in the lungs creates advantageous conditions for several opportunistic pathogens to cause infections, including

*S maltophilia*, in addition obstruction has been shown to be an independent risk factor for a poor outcome.<sup>3</sup> In line with the findings of other studies, we have demonstrated that most of the affected patients were very young or older than 50 years of age (78.46% of patients in the present study), with an observed male dominance in the patient population. A possible explanation for this phenomenon is that males are more prone to contract *S maltophilia*, due to their activities in the outdoors/aquatic environments.<sup>3</sup> Based on our results, we have noted an increase in the isolation rate of *S maltophilia* from LRTI samples, in addition to an increase in its prevalence in out-patient settings. The introduction of MALDI-TOF MS in our institute may explain the increase in the detection of these species; additionally, carbapenem prescription levels (both in the region and in Hungary overall) have increased dramatically (mainly due to the emergence of ESBL-positive strains) which may also have resulted in a more pronounced selection pressure for *S maltophilia* isolates.<sup>49</sup>

The local levels of SMX/TMP resistance were similar to those found in the global literature (Western Hemisphere: 2%-10%; however, some outliers with higher resistance levels [eg, Spain: 27%; Turkey 10%-15%] in Europe and Asia [Taiwan: > 25%; China: 30%-48%]) but somewhat higher than the European average.<sup>7</sup> In a similar study recently published by Gajdács et al in the same geographical region, 16.0% of isolates from bacteremia were resistant to SMX/TMP, and of these resistant strains, 32.7% were also resistant to levofloxacin, tigecycline, and colistin (thus, 5.2% overall were XDR isolates).<sup>29</sup> In contrast, during our current study regarding respiratory isolates, it was found that the levels of SMX/TMP and LEV resistance were lower (12.1% and 8.99%, respectively), while the ratio of XDR isolates was higher, recorded at 5.87%. It must be noted that in patients with malignant neoplasms, ICU patients, and patients with CF, resistance levels may be even higher (20%-80%).<sup>4</sup> The matter of SMX/TMP resistance is complex, as there is no definite consensus or guideline on the susceptibility testing and interpretation (breakpoints) for *S maltophilia* for several antibiotics, which may lead to confusion when interpreting published clinical data. Institutions must establish therapeutic protocols for these cases based on local resistance trends and international guidelines. In addition, more studies are needed to assess the relevance of various combination therapies in a controlled clinical setting.<sup>50</sup>

Several limitations of this study should be acknowledged. First, due to the inability to access the medical records of the individual affected patients, the presence and nature of symptoms of the patients were unknown. Additionally, the correlation between the presence/absence of all relevant risk factors and *S maltophilia* isolation from the respiratory tract could not be assessed. There is also a risk of selection/referral bias, as studies describing the prevalence of infectious diseases and resistance trends are mainly tertiary-care centers, which generally correspond to patients with more severe conditions or underlying illnesses, compared to community-based settings.<sup>29</sup>

In this present study, we observed the increasing prevalence of *S maltophilia* from respiratory tract specimens; the increase

**Table 2.** Summary of the Literature Regarding Susceptibility Trends of *Stenotrophomonas maltophilia* From Respiratory Tract Isolates

First Author	Study Years	Country	Number of Centers	% of Respiratory Isolates in the Study	Ratio of Susceptible Isolates							Susceptibility to Additional Antibiotics Patient Data (if available)
					SMX/TMP	CIP or LEV	TIC/CLAV	CEFTZ	MINO	COL		
Vartivarian et al <sup>31</sup>	1991-1994	United States (Texas)	Single center	29.2	75.0%	16.0%	43.0%	78.0%	97.0%	—	—	—
Gopalakrishnan et al <sup>32</sup>	1995-1996	United States (Miami)	Two community hospitals	88.5	95.1%	—	—	—	—	—	—	51% male patients; average age: 62 years; 88.8% mechanical ventilation
Aisenberg et al <sup>33</sup>	1997-2004	United States (Texas)	Single center	100	93%-95%	—	64%-70%	—	—	—	—	Male dominance (63%); average age: 58-63 years; 59.25% neutropenic and/or ICU patient
Sader et al <sup>34</sup>	1997-2001	SENTRY (Latin America)	Multicenter	100	100%	90.0%	51.7%	46.7%	—	59.2%	—	—
Gülmez et al <sup>35</sup>	1998-2003	Turkey	Single center	40.0	71.7%	CIP: 7.8%	—	—	—	—	—	AMK susceptibility: 15.1%; PIP/TAZO susceptibility: 2.2%
Tan et al <sup>36</sup>	1999-2004	China (Taiwan)	Single center	85.7	—	—	—	—	—	—	—	Male dominance (64.7%); average age: 73 years; 70% of isolates were extensively drug resistant (XDR) <i>S maltophilia</i> (SMX/TMP + fluoroquinolone + third agent)
Gales et al <sup>20</sup>	2001-2004	SENTRY (International)	Worldwide	100	97.0%	86.9%	47.6%	52.4%	—	—	—	—
Farell et al <sup>36</sup>	2003-2008	International	Worldwide	37.0	96.0%	83.4%	—	48.8%	—	64.6%	—	TGC susceptibility: 95.5%
Naeem et al <sup>37</sup>	2003-2009	Saudi Arabia	Single center	59.0	90.6%	23.0%	—	42.8%	—	—	—	PIP/TAZO susceptibility: 39.2%; GEN susceptibility: 12.6%; male dominance (56.3%); patients older than 50 years: 47.3%; patients in ICU 60.4%
Saguel et al <sup>38</sup>	2005-2009	Germany	Single center	100	>95.0%	—	—	—	—	80.0%	—	Male dominance (66.0%); 100% ICU patients
Flores-Trevino et al <sup>39</sup>	2006-2013	Mexico	Two tertiary-care hospitals	61.3	67.2%	CIP: 38.7%; LEV: 95.8%	—	44.5%	—	—	—	AMK susceptibility: 14.3%; CHL susceptibility: 44.5%
Sun et al <sup>40</sup>	2006-2012	China	Single center	21.6	57.1%	83.3%	—	—	—	—	—	PIP/TAZO susceptibility: 76.2%
Gozel et al <sup>41</sup>	2006-2013	Turkey	Single center	50.7	100%	89.0%	—	22.0%	—	—	—	AMK susceptibility: 0%; average age: 68 years; male dominance (69.4%)
Rodriguez et al <sup>42</sup>	2007-2008	Brazil	Single center	100	98.4%	97.6%	77.0%	46.0%	—	—	—	—
Juhász et al <sup>43</sup>	2009-2011	Hungary	Single center	58.0	99.9%	75.0%	—	—	—	9.0%	—	TGC susceptibility: 12.0%

(continued)

Table 2. (continued)

First Author	Study Years	Country	Number of Centers	% of Respiratory Isolates in the Study	Ratio of Susceptible Isolates							Susceptibility to Additional Antibiotics Patient Data (if available)
					SMX/TMP	CIP or LEV	TIC/CLAV	CEFTZ	MINO	COL		
Jia et al <sup>44</sup>	2010-2012	China	Single center	83.3	74.3%	96.7%	-	-	-	99.5%	-	Male dominance (55.9%); most isolates originated from ICU patients and patients older than 60 years
Rutter et al <sup>45</sup>	2010-2014	United States (Kentucky)	Single center	100	91.0%	62.0%	-	-	-	100.0%	-	Cystic fibrosis patients; <i>S. maltophilia</i> was the third most common among nonfermenting gram-negative bacteria
Chawla et al <sup>46</sup>	2012-2013	India	Single center	100	72.7%	78.8%	-	-	-	-	-	Male dominance (72.7%), median age: 55 years, mechanical ventilation or chronic respiratory illness in the anamnestic data of patients
Madi et al <sup>47</sup>	2013-2015	Serbia	Single center	100	100%	100%	-	-	-	-	-	Respiratory samples from cystic fibrosis and noncystic fibrosis patients
Nayyar et al <sup>48</sup>	2015-2016	India	Single center	65.2	91.3%	80.0%	-	-	-	-	-	Pediatric patients; male dominance (78.2%)

Abbreviations: AMK, amikacin; CIP, ciprofloxacin; CEFTZ, ceftazidime; CHL, chloramphenicol; GEN, gentamicin; ICU, intensive care unit; LEV, levofloxacin; MINO, minocycline; PIP/TAZO, piperacillin/tazobactam; SMX/TMP, sulfamethoxazole/trimethoprim; TIC/CLAV, ticarcillin/clavulanic acid; TGC, tigecycline; XDR, extensively drug resistant.

in prevalence may be due to the developments in diagnostic technologies in microbiology laboratories; however, there have been reports that isolation of *S maltophilia* increases proportionally with the utilization rate of carbapenem antibiotics (which provides selection pressure). Due to the increasing prevalence of extended-spectrum  $\beta$ -lactamase-producing gut bacteria in severe infections in Hungary, this observation correlates with the increased administration of carbapenems. The key points of the present study are the reporting of resistance trends of *S maltophilia* in the Central Eastern part of Europe, from where only few reports were published thus far; while the ratio of resistant strains to SMX/TMP and LEV (10.12% and 8.99%, respectively) is not outliers from the data found in the international literature, more than 1 of 20 of these respiratory isolates were representative of the XDR phenotype. For severely debilitated, immunocompromised patients, this corresponds to a very severe therapeutic conundrum, with little or no antimicrobial options left to treat them.<sup>1,29</sup> Both in the literature and based on our own results, *S maltophilia* was isolated with another significant pathogen. Therapeutically, this may bring forth additional challenges, especially if the mentioned copathogen is also resistant to several antibiotics (eg, ESBL *Enterobacteriaceae*, carbapenem-resistant *Pseudomonas* and *Acinetobacter*, and MRSA).<sup>51-53</sup> The use of inhalational/aerosolized antibiotics may have an important role in the therapy of these LRTI infections; their use is gaining increasing attention, in addition to combinational antibiotic therapy.

### Authors' Note

M.G. conceived and designed the study. E.U. was the senior microbiologist and performed the identification of the bacterial isolates during the study period. M.G. and E.U. performed data collection and analysis, wrote, and revised the full article.

### Acknowledgments

The authors would like to thank Tünde Deák and Erika Karasz for the excellent laboratory assistance during the routine diagnostic work.


### Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.G. was supported by the National Youth Excellence Scholarship [Grant Number NTP-NTFÖ-18-C-0225] and the ESCMID Mentorship and Observership Programme.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### ORCID iD

Márió Gajdács  <https://orcid.org/0000-0003-1270-0365>

### References

- Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. *Front Microbiol.* 2017;8:2276.
- Carmody LA, Spilker T, LiPuma JJ. Reassessment of Stenotrophomonas maltophilia phenotype. *J Clin Microbiol.* 2011;49(3):1101-1103.
- Singhal L, Kaur P, Gautam V. Stenotrophomonas maltophilia: from trivial to grievous. *Indian J Med Microbiol.* 2017;35(4):469-479.
- Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. *Clin Microbiol Rev.* 2012;25(1):2-41.
- Cervia JS, Ortolano GA, Canonica FP. Hospital tap water as a source of Stenotrophomonas maltophilia infection. *Clin Infect Dis.* 2008;46(9):1485-1487.
- Looney WJ. Role of Stenotrophomonas maltophilia in hospital-acquired infection. *Br. J. Biomed Sci.* 2005;62(3):145-154.
- Brooke JS. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. *Expert Rev Anti Infect Ther.* 2014;12(1):1-4.
- Gulcan H, Kuzucu C, Durmaz R. Nosocomial Stenotrophomonas maltophilia cross-infection: three cases in newborns. *Am J Infect Control.* 2004;32(6):365-368.
- Rajkumari N, Mathur P, Gupta AK, Sharma K, Misra M.C. Epidemiology and outcomes of Stenotrophomonas maltophilia and Burkholderia cepacia infections among trauma patients of India: a five year experience. *J Infect Prev.* 2015;16(3):103-110.
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. *Clin. Microbiol. Rev.* 1998;11(1):57-80.
- Gilardi GL. Pseudomonas maltophilia infections in man. *Am J Clin Pathol.* 1969;51(1):58-61.
- Wang Y, He T, Shen Z, Wu C. Antimicrobial resistance in Stenotrophomonas spp. *Microbiol Spectr.* 2018;6(1):1-14.
- Schaumann R, Knoop N, Genzel GH, et al. Discrimination of enterobacteriaceae and non-fermenting gram negative bacilli by MALDI-TOF mass spectrometry. *Open Microbiol J.* 2013;7:118-122.
- Steensels D, Verhaegen J, Lagrou K. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological laboratory: a review. *Acta Clin Belg.* 2011;66(4):267-273.
- Gautam V, Sharma M, Singhal L, et al. MALDI-TOF mass spectrometry: An emerging tool for unequivocal identification of non-fermenting Gram-negative bacilli. *Indian J Med Res.* 2017;145(5):665-672.
- Falagas M.E, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired stenotrophomonas maltophilia infections: a systematic review. *Eur J Clin Microbiol Infect Dis.* 2009;28(7):719-730.
- Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. *Future Microbiol.* 2009;4(9):1103-1109.
- del Toro MD, Rodríguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. *Medicine (Baltimore).* 2002;81(3):228-239.
- Al-Anazi KA, Al-Jasser AM. Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation. *Front Oncol.* 2014;4:232.

20. Gales A.C, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). *Clin Infect Dis*. 2001;32(suppl 2):S104-113.
21. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. *J Cyst Fibros*. 2009;8(6):386-391.
22. Bostanghadiri N, Ghalavand Z, Fallah F. Characterization of phenotypic and genotypic diversity of *Stenotrophomonas maltophilia* strains isolated from selected hospitals in Iran. *Front Microbiol*. 2019;10:1191.
23. Di Bonaventura G, Pompilio A, Zappacosta R, et al. Role of excessive inflammatory response to *Stenotrophomonas maltophilia* lung infection in DBA/2 mice and implications for cystic fibrosis. *Infect Immun*. 2010;78(6):2466-2476.
24. Pompilio A, Ciavardelli D, Crocetta V, et al. *Stenotrophomonas maltophilia* virulence and specific variations in trace elements during acute lung infection: implications in cystic fibrosis. *PLoS One*. 2014;9(2):e88769.
25. Berdah L, Taytard J, Leyronnas S, Clement A, Boelle PY, Corvol H. *Stenotrophomonas maltophilia*: a marker of lung disease severity. *Pediatr Pulmonol*. 2018;53(4):426-430.
26. Barsky EE, Williams KA, Priebe GP, Sawicki GS. Incident *Stenotrophomonas maltophilia* infection and lung function decline in cystic fibrosis. *Pediatr Pulmonol*. 2017;52(10):1276-1282.
27. Ko JH, Kang CI, Cornejo-Juárez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of *Stenotrophomonas maltophilia* infections: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2019;25(5):546-554.
28. Gajdács M. The concept of an ideal antibiotic: implications for drug design. *Molecules*. 2019;24(5):E892.
29. Gajdács M, Urbán E. Epidemiological trends and resistance associated with *Stenotrophomonas maltophilia* bacteremia: a 10-year retrospective cohort study in a tertiary-care hospital in Hungary. *Diseases*. 2019;7(2):E41.
30. Gajdács M, Spengler G, Urbán E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: Rubik's cube of clinical microbiology? *Antibiotics*. 2017;6(4):E25.
31. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of *Xanthomonas maltophilia* to antimicrobial agents: implications for therapy. *Antimicrob Agents Chemother*. 1994;38(3):624-627.
32. Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. *Stenotrophomonas maltophilia* infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. *Heart Lung*. 1999;28(2):134-141.
33. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. *Stenotrophomonas maltophilia* pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. *Eur J Clin Microbiol Infect Dis*. 2007;26(1):13-20.
34. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: latin American and Brazilian results for 1997 through 2001. *Braz J Infect Dis*. 2004;8(1):25-79.
35. Gülmez D, Hasçelik G. *Stenotrophomonas maltophilia*: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. *Clin Microbiol Infect*. 2005;11(11):880-886.
36. Tan CK, Liaw SJ, Yu CJ, Teng LJ, Hsueh PR. Extensively drug-resistant *Stenotrophomonas maltophilia* in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features, and outcomes. *Diagn Microbiol Infect Dis*. 2008;60(2):205-210.
37. Naeem T, Absar M, Somily AM. Antibiotic resistance among clinical isolates of *Stenotrophomonas maltophilia* at a teaching hospital in Riyadh, Saudi Arabia. *J Ayub Med Coll Abbottabad*. 2012;24(2):30-33.
38. Saugel B, Eschermann K, Hoffmann R, et al. *Stenotrophomonas maltophilia* in the respiratory tract of medical intensive care unit patients. *Eur J Clin Microbiol Infect Dis*. 2012;31(7):1419-1428.
39. Flores-Treviño S, Gutiérrez-Ferman JL, Morfín-Otero R, et al. *Stenotrophomonas maltophilia* in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. *J Med Microbiol*. 2014;63(pt 11):1524-1530.
40. Sun E, Liang G, Wang L, et al. Antimicrobial susceptibility of hospital acquired *Stenotrophomonas maltophilia* isolate biofilms. *Braz J Infect Dis*. 2016;20(4):365-373.
41. Gokhan Gozel M, Celik C, Elaldi N. *Stenotrophomonas maltophilia* infections in adults: primary bacteremia and pneumonia. *Jundishapur J Microbiol*. 2015;8(8):e23569.
42. Rodrigues LS, Gioia TSRD, Rossi F. *Stenotrophomonas maltophilia*: resistência emergente ao SMX-TMP em isolados brasileiros. uma realidade? *J Brasileiro de Patologia e Med Lab*. 2011;47:511-517.
43. Juhász E, Krizsán G, Lengyel G, Grósz G, Pongrácz J, Kristóf K. Infection and colonization by *Stenotrophomonas maltophilia*: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. *Ann Clin Microbiol Antimicrob*. 2014;13:333.
44. Jia W, Wang J, Xu H, Li G. Resistance of *Stenotrophomonas maltophilia* to fluoroquinolones: prevalence in a university hospital and possible mechanisms. *Int J Environ Res Public Health*. 2015;12(5):5177-5195.
45. Rutter WC, Burgess DR, Burgess DS. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. *Microb Drug Resist*. 2017;23(1):51-55.
46. Chawla K, Vishwanath S, Gupta A. *Stenotrophomonas maltophilia* in lower respiratory tract infections. *J Clin Diagn Res*. 2014;8(12):DC20-DC22.
47. Madi H, Lukić J, Vasiljević Z, et al. Genotypic and phenotypic characterization of *Stenotrophomonas maltophilia* strains from a pediatric tertiary care hospital in Serbia. *Plos One*. 2016;11(10):e0165660.
48. Nayyar C, Thakur P, Tak V, Saigal K. *Stenotrophomonas maltophilia*: an emerging pathogen in paediatric population. *J Clin Diagn Res*. 2017;11(1):DC08-DC11.
49. Benkő R, Matuz M, Hajdú E, et al. [Antibiotic use in the Hungarian hospitals in the last two decades (1996-2015)]. *Orv Hetil*. 2016;157(46):1839-1846.
50. Araoka H, Baba M, Okada C, Abe M, Kimura M, Yoneyama A. Evaluation of trimethoprim-sulfamethoxazole based combination



- therapy against *Stenotrophomonas maltophilia*: in vitro effects and clinical efficacy in cancer patients. *Int J Infect Dis.* 2017;58:18-21.
51. Aşık G, Çiftçi IH, Aktepe OC, Çetinkaya Z, Altındış M. In vitro activity of fosfomycin against extended spectrum- $\beta$ -lactamase (ESBL) producing *Escherichia coli* and *Klebsiella pneumoniae* strains. *Turk J Immunol.* 2008;13(1):1-4.
52. Gajdács M. The continuing threat of methicillin-resistant *Staphylococcus aureus*. *Antibiotics.* 2019;8(2):E52.
53. Codjoe FS, Donkor ES. Carbapenem Resistance: a review. *Med Sci (Basel).* 2017;6(1):1.

### Author Biographies

**Márió Gajdács** graduated as a Doctor of Pharmacy (PharmD) at the University of Szeged in 2016 and as a medical translator-interpreter

in 2018. He received his PhD from the Experimental chemotherapy/Medical microbiology program of the Faculty of Medicine, University of Szeged. He is currently in the process of becoming a specialized pharmacist in “Pharmacology, pharmacotherapy” and an assistant professor at the Department of Pharmacodynamics and Biopharmacy, Faculty of Medicine, University of Szeged.

**Edit Urbán** graduated as a Doctor of Pharmacy (PharmD) at the University of Szeged in 1989, as a specialist in laboratory medicine in 1996, and as a clinical microbiologist in 1999. She received her PhD in Clinical microbiology in 2002 from the Faculty of Medicine, University of Szeged. She is currently a full professor at the University of Szeged.